drugset
drugset / Trial / NCT05890742

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

NCT05890742 ↗

Phase 3 Active not recruiting 453 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer

Timeline

Start
2023-05-25
Primary completion
2028-04-15
Completion
2028-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI310 Monoclonal antibody 1 mg/kg —
Comparator Sintilimab Monoclonal antibody 200 mg —

Indications

No indication recorded.